DZIP1抗体;DZIP1 Antibody—艾普蒂

+ +

•  

   

     Gel: 6%SDS-PAGE, Lysate: 40 μg, Lane: PC-3 cell lysate, Primary antibody: P13291(DZIP1 Antibody) at dilution 1/200, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 5 minutes    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P13291(DZIP1 Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human brain tissue using P13291(DZIP1 Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

DZIP1 (DAZ Interacting Protein 1) is a conserved protein implicated in ciliogenesis, cell cycle regulation, and Hedgehog signaling pathways. Initially identified through its interaction with DAZ (Deleted in Azoospermia) proteins, DZIP1 plays critical roles in germ cell development, particularly during spermatogenesis, and is essential for primary cilium formation in vertebrates. Its dysfunction has been linked to ciliopathies, reproductive disorders, and certain cancers.

The DZIP1 antibody is a research tool designed to detect and quantify endogenous DZIP1 protein levels in various experimental models, including cell lines, tissues, and developmental organisms. It is commonly utilized in techniques such as Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to study DZIP1's localization, expression patterns, and interactions. Commercial DZIP1 antibodies are typically raised in hosts like rabbits or mice, targeting specific epitopes within the protein’s N-terminal or C-terminal regions. Validation often includes knockout cell line controls to ensure specificity.

Research applications focus on elucidating DZIP1's role in embryonic development, cilia-related pathologies, and cancer mechanisms, such as its tumor-suppressive activity in hepatocellular carcinoma (HCC). Reliable DZIP1 antibodies are crucial for advancing studies in developmental biology, reproductive health, and ciliopathy-related therapeutics.